|
Schizophrenia
|
0.410 |
GeneticVariation
|
disease |
GWASCAT |
Genome-Wide Association Study Detected Novel Susceptibility Genes for Schizophrenia and Shared Trans-Populations/Diseases Genetic Effect.
|
30285260 |
2019 |
|
Schizophrenia
|
0.410 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association analysis identifies 30 new susceptibility loci for schizophrenia.
|
28991256 |
2017 |
|
Schizophrenia
|
0.410 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study of schizophrenia in Ashkenazi Jews.
|
26198764 |
2015 |
|
Schizophrenia
|
0.410 |
Biomarker
|
disease |
PSYGENET |
Increased expression of receptor phosphotyrosine phosphatase-β/ζ is associated with molecular, cellular, behavioral and cognitive schizophrenia phenotypes.
|
22832403 |
2011 |
|
Schizophrenia
|
0.410 |
AlteredExpression
|
disease |
BEFREE |
Increased expression of receptor phosphotyrosine phosphatase-β/ζ is associated with molecular, cellular, behavioral and cognitive schizophrenia phenotypes.
|
22832403 |
2011 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
The aim of the study is to demonstrate the effect of Romidepsin in hepatocellular carcinoma (HCC) by inducing G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis through JNK/c-Jun/caspase3 pathway in vitro and in vivo.
|
28012958 |
2017 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
These findings suggest that UCN-01 induces hepatoma cell growth inhibition by regulating the p53/p21(waf1) and CHK2/CDC25 pathways.
|
23537372 |
2013 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
These findings indicate that DHM inhibits the growth of hepatocellular carcinoma (HCC) cells via G2/M phase cell cycle arrest through Chk1/Chk2/Cdc25C pathway.
|
24002546 |
2013 |
|
Liver carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma.
|
22228034 |
2012 |
|
Liver carcinoma
|
0.350 |
AlteredExpression
|
disease |
BEFREE |
To investigate the potential roles of CDC25s in hepatocellular carcinoma (HCC), expression of CDC25A and CDC25B was examined in human HCC samples.
|
12738732 |
2003 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CDC25 phosphatases play a critical role in the regulation of the cell cycle and thus represent attractive cancer therapeutic targets.
|
31294975 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CDC25B was primarily cytoplasmic in skin and skin tumors and was significantly increased in the squamous cell carcinoma (SCC), while CDC25C was mostly nuclear in the skin, with an increased cytoplasmic signal in the premalignant and malignant tumors.
|
31237025 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, it is extremely important to discover novel small molecule inhibitors with potent activities and significant selectivity for Cdc25 subtypes, not only served as drugs to treat cancer but also to probe its mechanism in transitions.
|
31541869 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Pharmacophore-guided discovery of CDC25 inhibitors causing cell cycle arrest and tumor regression.
|
30718768 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Consequently, we hypothesized that increased expression of CDC25B and CDC25C increases tumor cell proliferation and skin tumor growth.
|
31237025 |
2019 |
|
Eosinophil count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Duration of sleep
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association study identifies genetic loci for self-reported habitual sleep duration supported by accelerometer-derived estimates.
|
30846698 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
CDC25 phosphatases play a critical role in the regulation of the cell cycle and thus represent attractive cancer therapeutic targets.
|
31294975 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, it is extremely important to discover novel small molecule inhibitors with potent activities and significant selectivity for Cdc25 subtypes, not only served as drugs to treat cancer but also to probe its mechanism in transitions.
|
31541869 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We assessed Plk1 expression in five chemoresistant cancer cell types and found that Plk1 and its downstream phosphatase Cdc25c were selectively overexpressed in tamoxifen-resistant MCF-7 (TAMR-MCF-7) breast cancer cells.
|
29437878 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We assessed Plk1 expression in five chemoresistant cancer cell types and found that Plk1 and its downstream phosphatase Cdc25c were selectively overexpressed in tamoxifen-resistant MCF-7 (TAMR-MCF-7) breast cancer cells.
|
29437878 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cdc25 phosphatase B, a potential target for cancer therapy, is inhibited by a series of quinones.
|
28994029 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
KFEE effectively inhibited cancer cell proliferation, induced G2/M-phase arrest associated with downregulaton of cyclin E, cyclin B and cdc25C and upregulation of p21, and induced cell death by activating autophagy but did not cause apoptotic cell death.
|
27880045 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cdc25 phosphatase was studied as an attractive target for cancer therapy.
|
28198152 |
2017 |